• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Prescribing drugs for Alzheimer's disease in primary care: managing cognitive symptoms.

出版信息

Drug Ther Bull. 2014 Jun;52(6):69-72. doi: 10.1136/dtb.2014.6.0261.

DOI:10.1136/dtb.2014.6.0261
PMID:24924683
Abstract

There are currently no interventions that cure or even alter the progressive course of dementia. In the UK, donepezil, galantamine and rivastigmine are licensed for symptomatic treatment of mild to moderate Alzheimer's disease, and memantine is licensed for use in moderate to severe Alzheimer's disease.1-4 These drugs improve cognitive function by a modest amount compared with placebo.5 Although the National Institute for Health and Care Excellence (NICE) stipulates that such treatment should be initiated by a specialist, in many parts of the UK responsibility for continued prescription of these drugs is being transferred to primary care. Here we review the evidence for drugs prescribed for cognitive symptoms in Alzheimer's disease and highlight key issues for those who are prescribing them.

摘要

相似文献

1
Prescribing drugs for Alzheimer's disease in primary care: managing cognitive symptoms.
Drug Ther Bull. 2014 Jun;52(6):69-72. doi: 10.1136/dtb.2014.6.0261.
2
Prescribing of drugs for Alzheimer's disease: a South African database analysis.治疗阿尔茨海默病的药物处方:南非数据库分析。
Int Psychogeriatr. 2010 Mar;22(2):264-9. doi: 10.1017/S1041610209991530. Epub 2010 Jan 13.
3
A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.多奈哌齐与加兰他敏治疗阿尔茨海默病认知症状的比较:一项荟萃分析。
Hum Psychopharmacol. 2005 Apr;20(3):183-7. doi: 10.1002/hup.676.
4
Prescribing trends in cognition enhancing drugs in Australia.在澳大利亚,认知增强药物的处方趋势。
Int Psychogeriatr. 2011 Mar;23(2):238-45. doi: 10.1017/S1041610210001146. Epub 2010 Jul 30.
5
The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.中重度阿尔茨海默病认知增强剂的药物经济学。
CNS Drugs. 2010 Nov;24(11):909-27. doi: 10.2165/11539530-000000000-00000.
6
Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.认知增强剂(益智药)。第2部分:与酶相互作用的药物。2014年更新
J Alzheimers Dis. 2014;42(1):1-68. doi: 10.3233/JAD-140402.
7
National Institute for Clinical Excellence. Alzheimer's drugs given go-ahead.
Nurs Times. 2001;97(4):7.
8
Galantamine for Alzheimer's disease and mild cognitive impairment.加兰他敏用于治疗阿尔茨海默病和轻度认知障碍。
Neuroepidemiology. 2007;28(2):116-7. doi: 10.1159/000101510. Epub 2007 Apr 4.
9
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.多奈哌齐、卡巴拉汀、加兰他敏和美金刚用于治疗成年唐氏综合征患者阿尔茨海默病性痴呆的综述:对智力残疾人群的启示
Int J Geriatr Psychiatry. 2004 Jun;19(6):509-15. doi: 10.1002/gps.1077.
10
A population-based study of dosing and persistence with anti-dementia medications.基于人群的抗痴呆药物剂量和持续使用研究。
Eur J Clin Pharmacol. 2013 Jul;69(7):1467-75. doi: 10.1007/s00228-013-1483-y. Epub 2013 Feb 27.